330.92
전일 마감가:
$334.66
열려 있는:
$330.68
하루 거래량:
935.19K
Relative Volume:
1.08
시가총액:
$23.38B
수익:
$3.22B
순이익/손실:
$542.70M
주가수익비율:
44.24
EPS:
7.4805
순현금흐름:
$458.00M
1주 성능:
+4.62%
1개월 성능:
+1.53%
6개월 성능:
+23.96%
1년 성능:
+45.33%
West Pharmaceutical Services Inc Stock (WST) Company Profile
명칭
West Pharmaceutical Services Inc
전화
(610) 594-2900
주소
530 HERMAN O. WEST DRIVE, EXTON, PA
Compare WST vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services Inc
|
330.92 | 23.64B | 3.22B | 542.70M | 458.00M | 7.4805 |
|
ISRG
Intuitive Surgical Inc
|
412.02 | 151.09B | 10.58B | 3.00B | 2.83B | 8.2437 |
|
BDX
Becton Dickinson Co
|
147.79 | 41.89B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
66.11 | 33.11B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
36.54 | 30.45B | 29.14B | 1.07B | 1.05B | 1.1956 |
|
RMD
Resmed Inc
|
193.57 | 28.57B | 5.54B | 1.52B | 1.74B | 10.37 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-09-15 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-24 | 개시 | Barclays | Equal Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-01-08 | 개시 | Citigroup | Buy |
| 2024-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2024-12-12 | 업그레이드 | UBS | Neutral → Buy |
| 2024-02-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-06-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-04-11 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-11-30 | 개시 | UBS | Neutral |
| 2022-10-28 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-10-14 | 개시 | Stephens | Equal-Weight |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-04-24 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-12-12 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-07-26 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-05-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-04-23 | 개시 | William Blair | Outperform |
| 2018-04-25 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-10-03 | 개시 | Stephens | Equal-Weight |
| 2017-09-15 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-10-28 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-09-21 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2016-03-22 | 개시 | Wells Fargo | Outperform |
| 2010-05-14 | 재확인 | UBS | Neutral |
| 2010-02-23 | 개시 | Jefferies & Co | Buy |
| 2008-12-19 | 개시 | UBS | Neutral |
모두보기
West Pharmaceutical Services Inc 주식(WST)의 최신 뉴스
Reasons to Add Veeva Systems Stock to Your Portfolio for Now - TradingView
AMN Expands Language Services Portfolio With Jaide Health Deal - TradingView
Here's what to expect from West Pharmaceutical's next earnings report - MSN
Is Wall Street bullish or bearish on West Pharmaceutical Services stock? - MSN
West Pharma raised to overweight at Barclays on fundamentals - MSN
West Pharmaceutical Services Inc (WST) Shares Surge 4.7% -- What GF Score of 96 Tells Investors - GuruFocus
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
Barclays Upgrades West Pharmaceutical Services to Overweight From Equalweight, Adjusts PT to $400 From $310 - Moomoo
West Pharmaceutical (WST) Boosted to Overweight with Target Rais - GuruFocus
West Pharma stock upgraded at Barclays (WST:NYSE) - Seeking Alpha
West Pharmaceutical Services stock hits 52-week high at 331.43 USD - Investing.com
Barclays upgrades West Pharmaceutical stock rating on GLP-1 outlook By Investing.com - Investing.com Canada
Wolfe Research Says West Pharmaceutical Services (WST) is Positioned to Benefit from Injectable Drug Growth - Insider Monkey
Why Is West Pharmaceutical Drawing Attention Amid Injectable Drug Expansion? - Kalkine Media
West Pharmaceutical Services names Michel Lagarde as next CEO, effective Aug. 31 - MSN
Wolfe Research Weighs on West Pharmaceutical Services Inc (WST) Stock - Insider Monkey
How The West Pharmaceutical Services (WST) Story Is Evolving With Guidance Buybacks And New Leadership - Yahoo Finance
WST Technical Analysis | Trend, Signals & Chart Patterns | WEST PHARMACEUTICAL SERVICES (NYSE:WST) - ChartMill
Exton's West Pharmaceutical Services Names New CEO as Eric Green Steps Down After 11 Years - VISTA.Today
What Does Eric Green's Retirement Mean for West Pharmaceutical Services - Kavout
West Pharma names former Thermo Fisher executive Lagarde as CEO - ETPharma.com
Billionaire Bill Gates' Foundation Dumped Microsoft but Loaded Up on This Dividend Champion - Yahoo Finance
West Pharmaceutical Names Michel Lagarde Next CEO - The Globe and Mail
Billionaire Bill Gates' Foundation Dumped Microsoft but Loaded Up on This Dividend Champion - The Motley Fool
West Pharmaceutical Services Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
West Pharmaceutical Services Inc at William Blair Growth Stock Conference Transcript - GuruFocus
West Pharmaceutical Services (WST) Announces Leadership Transiti - GuruFocus
Q1 2026 Life Sciences Earnings Review: PacBio vs. West Pharmaceutical PerformanceNews and Statistics - IndexBox
WST Reiterated by Stephens & Co. -- Price Target Maintained at $360 - GuruFocus
BofA Securities Maintains West Pharmaceutical Services(WST.US) With Buy Rating - Moomoo
West Appoints Michel Lagarde a President and CEO - Contract Pharma
Here's Why You Should Retain AMN Stock in Your Portfolio for Now - TradingView
West Pharmaceutical Services Appoints Michel Lagarde as President and CEO Effective August 31, 2026 - Minichart
West Pharmaceutical (WST) Names Michel Lagarde as New CEO - GuruFocus
West Appoints Michel Lagarde to be President and Chief Executive Officer - GuruFocus
Wolfe Research initiates West Pharmaceutical stock with outperform rating By Investing.com - Investing.com India
Wolfe Research initiates West Pharmaceutical stock with outperform rating - Investing.com
West Pharmaceutical names Michel Lagarde as next CEO _newTouch_By Investing.com - Investing.com South Africa
West Pharmaceutical names Michel Lagarde as next CEO By Investing.com - Investing.com Canada
West Pharmaceutical Services Inc. stock underperforms Monday when compared to competitors - MarketWatch
West Pharmaceutical names Michel Lagarde as next CEO - Investing.com
West Pharmaceutical Services Inc (WST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
West Pharmaceutical Services Inc 주식 (WST) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Favorite Annette F | Sr. VP & Chief HR Officer |
Apr 27 '26 |
Option Exercise |
83.47 |
2,817 |
235,135 |
19,645 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Apr 27 '26 |
Sale |
305.20 |
2,817 |
859,753 |
16,828 |
| Winters Chad | VP, Chief Accounting Officer |
Apr 27 '26 |
Option Exercise |
173.22 |
896 |
155,205 |
2,419 |
| Winters Chad | VP, Chief Accounting Officer |
Apr 27 '26 |
Sale |
300.67 |
896 |
269,399 |
1,523 |
자본화:
|
볼륨(24시간):